| __timestamp | BioMarin Pharmaceutical Inc. | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 2232342000 |
| Thursday, January 1, 2015 | 402271000 | 2113100000 |
| Friday, January 1, 2016 | 476593000 | 1947900000 |
| Sunday, January 1, 2017 | 554336000 | 1935500000 |
| Monday, January 1, 2018 | 604353000 | 2106300000 |
| Tuesday, January 1, 2019 | 680924000 | 2374700000 |
| Wednesday, January 1, 2020 | 737669000 | 2504500000 |
| Friday, January 1, 2021 | 759375000 | 2674300000 |
| Saturday, January 1, 2022 | 854009000 | 2403600000 |
| Sunday, January 1, 2023 | 937300000 | 2549700000 |
| Monday, January 1, 2024 | 1009025000 | 2403700000 |
Unleashing the power of data
In the competitive world of biotechnology, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Biogen Inc. and BioMarin Pharmaceutical Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Biogen consistently outspent BioMarin, with its SG&A costs peaking at approximately 2.67 billion in 2021, a 38% increase from 2014. In contrast, BioMarin's expenses grew more steadily, reaching around 937 million in 2023, marking a 210% rise since 2014. This divergence highlights Biogen's aggressive market strategies compared to BioMarin's more measured approach. As these companies continue to innovate, their financial strategies will play a pivotal role in shaping their future trajectories. Investors and industry analysts should keep a keen eye on these trends to gauge the evolving landscape of the biotech sector.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
Merck & Co., Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Biogen Inc. or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and MannKind Corporation